Skip to main content

Table 2 Frequency and patients’ disposition of SARS-CoV-2 infection

From: Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

  Confirmed COVID-19 Highly suspicious COVID-19 Unlikely COVID-19 Non-COVID-19
  n = 23 n = 29 n = 261 n = 1737
Age, mean (SD), years 62.8 (13.1)*§ 52.8 (13.1)*§ 53.8 (14.6)*§ 58.5 (14.9)*§
Female gender, n (%) 15 (65.2) 21 (72.4) 178 (68.2) 1140 (65.6)
Current smokers, n (%) 4 (21.1) 3 (11.5) 38 (18.3) 231 (16.2)
BMI, median (IQR) 26.3 (7) 24.6 (4.3) 24.9 (5.4) 25.3 (5.1)
 Overweight, n (%) 4 (28.6) 7 (25.9) 53 (26.1)# 461 (33.6)#
 Obese, n (%) 3 (21.4) 4 (14.8) 33 (16.3) 193 (14.1)
Hypertension, n (%) 10 (50) 10 (37) 76 (30.6) 547 (32.5)
Diabetes, n (%) 2 (10) 1 (3.7) 22 (8.9) 133 (7.9)
Diagnosis
 SpA, n (%) 4 (17.4) 5 (17.2) 48 (18.4) 240 (13.8)
 PsA, n (%) 2 (8.7) 4 (13.8) 52 (19.9) 340 (19.6)
 UA, n (%) 0 (0) 4 (13.8) 11 (4.2) 112 (6.4)
 RA, n (%) 17 (73.9) 16 (55.2) 150 (57.5) 1045 (60.2)
Disease duration, median (IQR), months 96 (60–153) 96 (50–147) 120 (60–180) 120 (60–192)
 ≤ 5 years, n (%) 7 (30.4) 10 (35.4) 70 (27.1) 496 (28.7)
 5–10 years, n (%) 8 (34.8) 12 (41.4) 66 (25.6) 449 (26)
 10–15 years, n (%) 6 (26.1) 0 (0) 63 (24.4) 361 (20.9)
 > 15 years, n (%) 2 (8.7) 7 (24.1) 59 (22.9) 422 (24.4)
Use of PDN, n (%) 13 (56.5)** 9 (31) 73 (28)** 549 (31.7)**
PDN dose, mean (SD), mg/day 4.6 (1.4) 3.9 (2.2) 4.3 (2.1) 4.3 (3.5)
 < 2.5 mg/day, n (%) 0 (0) 2 (22.2) 6 (8.2) 49 (9)
 ≥ 2.5 mg/day, n (%) 13 (100) 7 (77.8) 67 (91.8) 498 (91)
Use of HCQ, n (%) 5 (21.7) 5 (17.2) 47 (18) 325 (18.7)
Use of csDMARDs, n (%) 15 (65.2) 13 (44.8) 153 (54.8) 877 (50.5)
Use of b/tsDMARDs, n (%) 10 (43.5)** 11 (37.9)^ 183 (70.1)**^ 1074 (61.8)^
  1. BMI body mass index, RA rheumatoid arthritis, UA undifferentiated arthritis, PsA psoriatic arthritis, SpA spondyloarthritis, PDN prednisone, HCQ hydroxychloroquine, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, b/tsDMARDs biological/targeted synthetic disease-modifying anti-rheumatic drugs
  2. *p < 0.05 for confirmed COVID-19 compared to all the other groups
  3. §p < 0.05 for non-COVID-19 compared to all the other groups
  4. #p < 0.05 for non-COVID-19 compared to unlikely COVID-19
  5. **p < 0.05 for confirmed COVID-19 compared to unlikely COVID-19
  6. ^p < 0.05 for probable COVID-19 compared to unlikely COVID-19 and non-COVID-19